Vol 27, No 5 (2020)
Research letters — Clinical cardiology
Published online: 2020-08-07
First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases
1
, 2, 2, 2, 1, 1, 1, 1, 1, 1, 1, 1
, 2, 2, 2, 1, 1, 1, 1, 1, 1, 1, 1
Abstract
Not available
References
- Lenzen M, Ryden L, Ohrvik J, et al. Euro Heart Survey Investigators. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006; 27(24): 2969–2974.
- Gasior M, Pres D, Stasik-Pres G, et al. Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol J. 2008; 15(5): 422–430.
- Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
- Kralev S, Krause B, Papavassiliu T, et al. Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors. Cardiol J. 2009; 16(3): 234–240.
- Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(19): 1880–1882.
- Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19): 1526–1534.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020; 382(10): 972–973.
- Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015; 314(1): 52–60.
- Sharma A, Zhao X, Hammill B, et al. Trends in noncardiovascular comorbidities among patients hospitalized for heart failure. Circ Hear Fail. 2018; 11(6).
